
A budget impact analysis of bezlotoxumab versus standard of care antibiotics only in patients at high risk of CDI recurrence from a hospital management perspective in Germany.
Jakobs F, Wingen-Heimann SM, Jeck J, Kron A, Cornely OA, & Kron F
1. September 2021